Treatment goals with psoriatic arthritis

[Fred]

This study asked “If you could improve one thing about your psoriatic arthritis, what would it be?” and “What would an effective treatment change for you?”

Quote:

---

Objective:
The aim was to examine patient-reported treatment goals among individuals with psoriatic arthritis (PsA).

Methods:
Participants in the Psoriatic Arthritis Research Consortium (PARC) completed standardized assessments including patient-reported outcome (PROs) instruments between 2017-2020. Additionally, participants were asked two open-ended questions at enrollment or therapy initiation “If you could improve one thing about your disease, what would it be?” and “What would an effective treatment change for you?” to identify patients’ top improvement priority and their treatment impact goals, respectively. We categorized each response into a theme. The themes were matched to constructs measured by PRO items (i.e., pain, fatigue, skin, etc.). We describe themes and scores from matched PRO items.

Results:
Assessments were completed by 193 participants. Decreasing pain (56%) and improving skin (12%) were the most common improvement priorities. Impact goals were more diverse and included decreasing pain (24%), general improvement in life (18%), the ability to be more active (15%), participate in recreational activities (9%), function at work (11%) and exercise (5%). Of note, responses were often matched to more than one PRO item or instrument. The scores for PRO items that matched the patient's improvement priority, or the impact goal were higher than scores for the remainder of the population (i.e., fatigue item scores were higher among individuals identifying fatigue as their improvement priority).

Conclusions:
The heterogeneity of treatment goals underscores the importance of eliciting patient treatment goals to guide personalized management. Specific items within PROs may be helpful in identifying and following patient-specific treatment goals.

Source: onlinelibrary.wiley.com

*Funding: Early view funding unknown